Suzanne E Schindler is an expert in Neurology at Washington University Medical Center (United States). As of October 2026, ScienceLeadR ranks Suzanne E Schindler in the top 1% of experts worldwide for Alzheimer Disease, Dementia and Neurocognitive Disorders. Suzanne E Schindler has authored 299 publications, the most recent in 2026. SLR score: 1,368 (community average: 125). How the SLR is computed.

LeadR Profile

Suzanne E Schindler Washington University Medical Center United States
1 368 ScienceLeadR Reputation 1368
Network Map

Neurology

Subspecialties: Psychiatry - Biochemistry - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2013 - 2026

Source: PubMed

Washington University in St. Louis

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 299

Citations

Citations: 5 607 1st author: 28 Last author: 24 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
CSF and plasma lipid profiling predicts risk of cognitive impairment in cognitively unimpaired older adults.
PMID 42947286 — dementia, alzheimer disease, cognitive dysfunction, biomarkers, cognition disorders, lipidomics, esters, plasma
Alzheimers Dement20260
Symmetric Centipolar Normalized Score (SCeNS): A standardization framework for fluid marker cross-comparability in Alzheimer's disease.
PMID 42935659 — alzheimer disease, biomarkers
Alzheimers Dement (Amst)20260
Simpson's Paradox, Amyloid Paradox, and Racial Differences.
PMID 42944683 — comorbidity, dementia, aging, cohort studies, clinical medicine, prevalence, amyloid, cognition
JAMA Netw Open20260
Mild Amyloid Burden in the Brains of Cognitively Unimpaired Individuals is Associated with Long-Term Cognitive Impairment.
PMID 42873601 — positron-emission tomography, brain, cognitive dysfunction, cognition disorders, amyloid
Ann Neurol20260
Alzheimer's disease heterogeneity and co-pathologies: Defining novel targets, biomarkers, modalities, and research methodologies.
PMID 42741654 — alzheimer disease, pathology, biomarkers, precision medicine, research, therapeutics, cerebral amyloid angiopathy
Alzheimers Dement (N Y)20260

LeadR Networks

Main global connection map